After Patient Death,FDA Places Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Trial

Pfizer DMD Gene Therapy Team . DMD study 1001 update: letter to the community, distributed via parent project muscular dystrophy. 2021. https://www.parentprojectmd.org/wp-content/uploads/2021/12/DMD-Study-1001-Update_Letter-to-the-Community.pdf (last accessed January 12, 2022 ).

Martinez-Navio JM , Paulk NK , Gao G . Editorial: “AAV gene therapy: immunology and immunotherapeutics.” Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.822389 (last accessed January 12, 2022 ).

Pfizer and Beam Therapeutics. Pfizer and Beam Enter exclusive multi-target research collaboration to advance novel in vivo base editing programs for a range of rare diseases. 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research (last accessed January 12, 2022 ).

Selecta Biosciences and Ginkgo Bioworks. Selecta Biosciences and Ginkgo Bioworks announce new collaboration to develop next-generation gene therapy capsids. 2022. https://investors.ginkgobioworks.com/news/news-details/2022/Selecta-Biosciences-and-Ginkgo-Bioworks-Announce-New-Collaboration-to-Develop-Next-Generation-Gene-Therapy-Capsids/default.aspx (last accessed January 13, 2022 ).

Bayer AG and Mammoth Biosciences . Bayer and Mammoth Biosciences to collaborate on novel gene editing technology . 2022. https://media.bayer.com/baynews/baynews.nsf/id/Bayer-and-Mammoth-Biosciences-to-collaborate-on-novel-gene-editing-technology (last accessed January 13, 2022 ).

Spark Therapeutics. Spark therapeutics to invest $575m in new 500k square foot state-of-the-art gene therapy innovation center on Drexel's university city campus. 2021. https://sparktx.com/press_releases/spark-therapeutics-to-invest-575m-in-new-500k-square-foot-state-of-the-art-gene-therapy-innovation-center-on-drexels-university-city-campus/ (last accessed January 13, 2022 ).

SK Inc . SK Inc. , becomes second-largest shareholder of the Center for Breakthrough Medicines , a U.S.-based Cell and Gene Therapy (CGT) CDMO, accelerating its growth as a global leader in the field. 2022. https://eng.sk.com/news/sk-inc-becomes-second-largest-shareholder-of-the-center-for-breakthrough-medicines-a-u-s-based-cell-and-gene-therapy-cgt-cdmo-accelerating-its-growth-as-a-global-leader-in-the-field (last accessed January 13, 2022 ).

Li C , Wang D , Song Y , et al. A phase 1/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and/or refractory multiple myeloma. Abstract #547, presented December 12, 2021, at the 63rd American Society of Hematology Annual Meeting. https://ash.confex.com/ash/2021/webprogram/Paper152576.html (last accessed January 13, 2022 ).

Sana Biotechnology IA , SO Biotherapeutics and Innovent Biologics . Sana Biotechnology IA , SO Biotherapeutics , and Innovent Biologics announce non-exclusive license agreement for clinically validated BCMA CAR construct . 2022. https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-iaso-biotherapeutics-and-innovent-biologics (last accessed January 13, 2022 ).

BioMarin Pharmaceutical. BioMarin announces stable and durable annualized bleed control in the largest phase 3 gene therapy study in adults with severe hemophilia a; 134-participant study met all primary and secondary efficacy endpoints at two year analysis. 2022. https://investors.biomarin.com/2022-01-09-BioMarin-Announces-Stable-and-Durable-Annualized-Bleed-Control-in-the-Largest-Phase-3-Gene-Therapy-Study-in-Adults-with-Severe-Hemophilia-A-134-Participant-Study-Met-All-Primary-and-Secondary-Efficacy-Endpoints-at-Two-Year-Analysis (last accessed January 13, 2022 ).